A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
Active, not recruiting · NCT07174726 · Registry updated 2026-06-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa | Eye Diseases, Hereditary, eye disorder, retinal degeneration, retinal disorder | Active, not recruiting | Phase 2 | 2026-06-25 | NCT07174726 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beacon Therapeutics | 5 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Bascom Palmer Eye Institute | Miami | United States | 17 |
| Cincinnati Eye Institute | Cincinnati | United States | 22 |
| Duke Eye Center | Durham | United States | 14 |
| OHSU Casey Eye Institute | Portland | United States | 4 |
| Retina Foundation of the Southwest | Dallas | United States | 38 |
| University of Florida Jacksonville Ophthalmology | Jacksonville | United States | 1 |